bupropion

AssetAlso bupropion hydrobromide, 323U66, Bupropion Hydrochloride Sustained Release, Bupropion Hydrochloride Extended-release

Inhibits norepinephrine and dopamine reuptake, increasing their availability in synapses.

Stage: Approved
Modality: Small molecule
Target: SLC6A2; 13
Indications: 219
Trials: 5
Developers

Indications

13

Depressive Disorder, Major
Approved, accessdata.fda.gov, 7 Oct 2026
Seasonal affective disorder
Approved, accessdata.fda.gov, 7 Oct 2026
Attention deficit disorder
Phase 3, Completed, NCT00048360, clinicaltrials.gov, 7 Oct 2026

10 more

In the full profile

Targets and what it contains5
Owner and partners5
Trials219
Evidence for its targets5
Competitors12
Signals14

Every asset’s record: target, stage, trials and the evidence behind it.

Updated 10 Oct 2026, 26 sources